Industrializing Manufacturing & Distribution
Friday, May 31, 2024 03:45 PM - 04:45 PM
Room 211
Launch and Patient Access
Concurrent Session
Chair
Cell therapies, from cancer to monogenetic diseases, continue to demonstrate clinical benefit. Recent regulatory approvals demonstrate the changing paradigm across the therapeutic landscape of future ‘curative’ across many unmet medical needs.
With continuing success comes increased responsibilities of;
(1) driving industrialization of manufacturing,
(2) reducing cost of goods while maintaining consistent product quality,
(3) demonstrating long-term durability of responses, in permitting democratized access to these therapies.
This session will showcase the current state of the industry and will highlight how the leaders in the field ate thinking of innovation in terms of NextGen Manufacturing, engineering processes to optimize fixed and operating cost considerations, reducing time in manufacturing and/or QC release, with advances in process & analytical technologies leading to accessibility / availability to such ‘curative’ therapies to patients.
- Madhusudan V. Peshwa, PhD, Tessera Therapeutics, United States
- Martin Westberg, Cytiva/Danaher, Sweden, "Collaborating to Advance Future Therapeutics -from Innovation to Industrialization"
- Simon Gardiner, PhD, Kite Pharma, United States
- Julie Allickson, PhD, Mayo Clinic Center for Regenerative Biotherapeutics & Biomanufacturing and Product Development & Center for Regenerative Biotherapeutics and Associate Professor of Regenerative Medicine, United States
- Nirupama Pike, MDS, PhD, Catalent Pharma Solutions, United States
Cell therapies, from cancer to monogenetic diseases, continue to demonstrate clinical benefit. Recent regulatory approvals demonstrate the changing paradigm across the therapeutic landscape of future ‘curative’ across many unmet medical needs.
With continuing success comes increased responsibilities of;
(1) driving industrialization of manufacturing,
(2) reducing cost of goods while maintaining consistent product quality,
(3) demonstrating long-term durability of responses, in permitting democratized access to these therapies.
This session will showcase the current state of the industry and will highlight how the leaders in the field ate thinking of innovation in terms of NextGen Manufacturing, engineering processes to optimize fixed and operating cost considerations, reducing time in manufacturing and/or QC release, with advances in process & analytical technologies leading to accessibility / availability to such ‘curative’ therapies to patients.
Julie Allickson
Director of Mayo Clinic's Center for Regenerative Biotherapeutics
Mayo Clinic
Panelist
Director of Mayo Clinic's Center for Regenerative Biotherapeutics
Mayo Clinic
Panelist
